BioSpace News Archive

Business

Investment Bankers Leave Firms for Roles in Hong Kong Biotech Companies

More and more pharma companies follow the trend of planning initial public offerings on the Hong Kong Stock Exchange. Another trend following this path is the number of prominent investment bankers who have left their firms for biotech companies in the former British colony.

July 9, 2018
·
2 min read
·
Alex Keown
Deals

Abingworth Closes on $315 Million Fund Aimed at Life Science Companies in Europe and the U.S.

Abingworth Bioventures closed out its latest investment fund aimed at supporting life science companies with $315 million. The latest fund, ABV VII, will be used to support investments in Europe and the United States.

July 9, 2018
·
2 min read
·
Alex Keown
Drug Development

Cytori Therapeutics Erectile Dysfunction Stem Cell Therapy Shows Positive Results in Early Trial

Cytori Therapeutics, headquartered in San Diego, published data from its clinical trial of Adipose-Derived Regenerative Cells (ADRCs) in the journal Urology showing positive results.

July 9, 2018
·
2 min read
·
Mark Terry
Drug Development

CTI Shares Plunge After NHL Treatment Fails in Phase III Trial

Shares of CTI BioPharma Corp. are down more than 15 percent in premarket trading this morning after the company announced its combination treatment for B-cell non-Hodgkin lymphoma failed to meet endpoints in a late-stage trial.

July 9, 2018
·
2 min read
·
Alex Keown
Business

Axovant Significantly Expands Pipeline with Licensing Deal with Benitec BioPharma

Axovant, one of Vivek Ramaswamy’s biotech companies best known for its catastrophic Alzheimer’s failure in September 2017, is replenishing its pipeline with a licensing deal with Australian company Benitec Biopharma.

July 9, 2018
·
3 min read
·
Mark Terry
Business

MabVax Secures $11 Million from Boehringer Ingelheim for Antibody Development Program

Shares of MabVax Therapeutics have more than doubled this morning after Boehringer Ingelheim inked a deal to acquire the rights to an antibody development program that will be used to target multiple solid tumors.

July 9, 2018
·
2 min read
·
Alex Keown
Deals

2018 Is a Hot Year for Biotech Startups, IPOs and M&A Activity

Despite market volatility, ongoing debates about drug pricing, and various scandals such as the Theranos debacle, everything Martin Shkreli touches, and Novartis paying President Trump’s attorney Michael Cohen $1.2 million for access to the president, it hasn’t slowed down biotech startups or investors.

July 9, 2018
·
2 min read
·
Mark Terry
Drug Development

Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma

PIXUVRI® plus rituximab did not show a statistically significant improvement in progression-free survival compared to gemcitabine plus rituximab

July 9, 2018
·
8 min read
Biotech Beach

Trovagene Presents Outlook for Second Half of 2018

Trovagene, Inc. provided an update on key value-creating milestones for the second half of 2018 and a review of its year-to-date achievements.

July 9, 2018
·
14 min read
FDA

Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%

Bausch + Lomb announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its sub-micron loteprednol etabonate ophthalmic gel

July 9, 2018
·
3 min read